EVEREST MED(01952): The related technology of the original research product Nai Fukang is protected in China by patent ZL200980127272.5, which is currently in force.

Everest MED (01952) Announcement: The company's board of directors has noticed that a generic version of the company's listed product Budesonide Enteric Capsules (Nefukang) has obtained approval for market authorization in China from the China National Medical Products Administration. The board emphasizes that the original research product Nefukang is protected by patent ZL200980127272.5 in China, which is currently in effect until May 7, 2029. The company has lawfully registered the relevant patent information on the Chinese Marketed Drug Patent Information Registration platform. In accordance with Article 11 of the Chinese Patent Law and the Implementation Measures for the Early Resolution of Medicine Patent Disputes (Trial) (the Measures), any enterprise or individual must not manufacture, use, promise sale (including marketing, application for listing, etc.), sell, or import products falling within the scope of the aforementioned patent protection for production and operation purposes without legal permission from the company before the expiry of the patent term. Otherwise, it will constitute patent infringement. According to the Measures, if the applicant for a generic drug makes a "Category 3 Declaration" (i.e., promising not to market the drug before the expiration of the relevant patent right), they should strictly abide by this commitment and fulfill their obligations in good faith. The company reserves the right to take all necessary legal actions against any suspected violations of the above provisions and commitments. The company is dedicated to introducing innovative therapies into China to meet the urgent medical needs. A sound patent protection system and effective Measures are crucial for ensuring the continuous accessibility of such groundbreaking innovative drugs, incentivizing pharmaceutical research and development innovation, and promoting fair and orderly competition in the generic drug industry based on respect for intellectual property rights. It is this system that safeguards the successful development and introduction of breakthrough therapies like Nefukang in China. In recent years, the intellectual property protection environment in the China Meheco Group industry has continued to improve, providing strong protection for pharmaceutical innovation and industry health. In the future, the company will continue to work with all parties to respect and protect intellectual property rights, adhere to relevant laws and regulations, create a legal and fair competitive environment, promote the continued development and accessibility of innovative drugs, and ultimately benefit a wide range of Chinese patients.